Early Access to Medicines Scheme (EAMS) – UK
MHRA EAMS Application with Promising Innovative Medicine (PIM) designationStatutory90 days
Description & Eligibility
EAMS provides patients with life-threatening or seriously debilitating conditions access to promising medicines before full marketing authorization. The scheme includes a scientific opinion from MHRA on the benefit-risk balance based on early clinical data.
Eligibility Criteria
Patients with life-threatening or seriously debilitating conditions with significant unmet medical need, no alternative treatment available
Legal Reference / Source
Early Access to Medicines Scheme Regulations 2014
Countries Using This Pathway (1)
Early Access to Medicines Scheme (EAMS) – UK
| Approval Form | MHRA EAMS Application with Promising Innovative Medicine (PIM) designation |
| Timeline | 90 days |
| Legal Status | Statutory |
| Source Ref. | Early Access to Medicines Scheme Regulations 2014 |
| Countries | 1 countries |
Compliance Check
Legal Review3/21/2026
Global ValidityVerified